CeNeRx BioPharma awarded patent for novel substances that selectively focus on peripheral cannabinoid receptors CeNeRx BioPharma, Inc. Offers announced issuance of a fresh U.S http://www.stanozolol10mg.com/ . Patent covering its novel compounds that focus on peripheral cannabinoid receptors. By avoiding the CNS, these substances are much less most likely to be associated with the side effects that have limited the utility of various other cannabinoid medications. Developed through its discovery partnership with PharmaNess Neuroscience, CeNeRx has a portfolio greater than a dozen preclinical compounds that selectively target peripheral CB1 and CB2 cannabinoid receptors.
If we can use stem cells to slow or stop heart harm, it could help stall progression of the disease.’ Related StoriesResearchers discover that stem cell treatment may decrease cognitive impairment linked to dementia with Lewy bodiesKey protein controls stem cell properties that will make them useful in regenerative medicineNYSCF meeting to spotlight translational stem cell and neuroscience researchThe first step in the study can be to examine the result of injecting cardiac stem cells in to the hearts of mice with Duchenne. If the data is usually positive, the experimental treatment could be quickly approved for use in human beings with Duchenne because of cardiac stem cell treatments have been approved for other patient populations, including those with advanced cardiovascular disease.